切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2020, Vol. 10 ›› Issue (06) : 248 -251. doi: 10.3877/cma.j.issn.2095-2015.2020.06.003

所属专题: 总编推荐 文献

临床研究

克罗恩病患者血浆中鸟苷与尿鸟苷水平的临床研究
徐东燕1, 张晓雨2, 赵海剑2, 王健2,(), 孙静3   
  1. 1. 223002 江苏省,淮安市第二人民医院消化内科
    2. 223002 江苏省,淮安市第二人民医院胃肠外科
    3. 214000 江苏省,南京医科大学附属无锡市人民医院消化内科
  • 收稿日期:2020-06-05 出版日期:2020-12-01
  • 通信作者: 王健
  • 基金资助:
    国家自然科学基金(81800490); 江苏省"333"高层次人才项目(BRA2017247); 江苏省六大人才高峰项目(WSW-220)

Clinical study on plasma levels of guanylin and uroguanylin in patients with Crohn disease

Dongyan Xu1, Xiaoyu Zhang2, Haijian Zhao2, Jian Wang2,(), Jing Sun3   

  1. 1. Department of Gastroenterology, Second People′s Hospital of Huai′an, Jiangsu Province, Huai′an 223002, China
    2. Department of Gastrointestinal Surgery, Second People′s Hospital of Huai′an, Jiangsu Province, Huai′an 223002, China
    3. Department of Gastroenterology, Wuxi People′s Hospital Affiliated to Nanjing Medical University, Wuxi 214000, China
  • Received:2020-06-05 Published:2020-12-01
  • Corresponding author: Jian Wang
引用本文:

徐东燕, 张晓雨, 赵海剑, 王健, 孙静. 克罗恩病患者血浆中鸟苷与尿鸟苷水平的临床研究[J]. 中华消化病与影像杂志(电子版), 2020, 10(06): 248-251.

Dongyan Xu, Xiaoyu Zhang, Haijian Zhao, Jian Wang, Jing Sun. Clinical study on plasma levels of guanylin and uroguanylin in patients with Crohn disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2020, 10(06): 248-251.

目的

评价克罗恩病(CD)患者血浆鸟苷前体激素(ProGN)和尿鸟苷前体激素(ProUGN)水平在临床中的价值。

方法

采用酶联免疫吸附试验(ELISA)对克罗恩病患者和健康对照者血浆ProGN和ProUGN水平进行检测,并分析其与临床疾病活动性及24 h大便次数的相关性。

结果

与健康对照者相比,CD患者血浆ProGN与ProUGN水平均明显降低(均P<0.05)。亚组分析显示,缓解期与活动期患者血浆ProGN水平均显著低于健康对照组(均P<0.001),活动期患者水平低于缓解期患者,但差异无统计学意义(P=0.121);缓解期患者血浆ProUGN水平显著低于健康对照组(P<0.001),活动期患者低于健康对照组,但差异无统计学意义(P=0.266);缓解期患者显著低于活动期患者,差异有统计学意义(P=0.011)。Pearson相关性分析显示,血浆ProGN及ProUGN水平与患者24 h大便次数均呈显著负相关(r=-0.804与r=-0.767,均P<0.001)。血浆ProGN水平与Best克罗恩病活动指数呈显著负相关(r=-0.561,P<0.001);而ProUGN水平与Best克罗恩病活动指数无线性相关(r=-0.155,P=0.314)。

结论

克罗恩病患者疾病临床活动性和腹泻可能是血浆ProGN水平的决定因素。

Objective

To evaluate the clinical value of ProGN and ProUGN in patients with Crohn disease(CD).

Methods

The plasma ProGN and ProUGN levels of Crohn disease patients and healthy controls were detected by enzyme-linked immunosorbent assay(ELISA), and the correlation between plasma levels and clinical disease activity and 24-hour stool frequency was analyzed.

Results

Compared with the healthy controls, the plasma ProGN and ProUGN levels of CD patients were significantly lower(P<0.05). Subgroup analysis showed that the plasma ProGN level of patients in remission period and active period was significantly lower than that of healthy control group(P<0.001), while the level of patients in active period was lower than that of patients in remission period, but there was no statistical significance(P=0.121); the plasma ProUGN level of patients in remission period was significantly lower than that in healthy control group(P<0.001), and plasma level of patients in active period was lower than that in healthy control group, but there was no statistical significance(P=0.266), and plasma level of patients in remission period was significantly lower than that in active period(P=0.011). Pearson correlation analysis showed that plasma ProGN and ProUGN levels were negatively correlated with 24-hour stool frequency(r=-0.804, P<0.001; r=-0.767, P<0.001). There was a significant negative correlation between the plasma ProGN level and the Best Crohn disease activity index(r=-0.561, P<0.001), but there was no linear correlation between the plasma ProGN level and the Best Crohn disease activity index(r=-0.155, P=0.314).

Conclusion

The clinical activity and diarrhea may be the determinants for level of proGN in plasma.

表1 克罗恩病患者与健康对照组血浆ProGN与ProUGN水平的比较(ng/ml)
图1 克罗恩病患者鸟苷前体激素(ProGN)和尿鸟苷前体激素(ProUGN)血浆水平亚组分析
图2 患者24 h大便次数与患者血浆鸟苷前体激素(ProGN)和尿鸟苷前体激素(ProUGN)水平相关性分析
图3 患者血浆鸟苷前体激素(ProGN)水平与疾病活动指数相关性分析
1
洪之武,任建安,黎介寿,等.克罗恩病合并肠瘘273例临床特征与预后分析[J].中国实用外科杂志,2019,39(5):492-496.
2
Basu N, Arshad N, Visweswariah SS.Receptor guanylyl cyclase C(GC-C):regulation and signal transduction[J].Mol Cell Biochem,2010,334:67-80.
3
Moss NG, Fellner RC, Qian X,et al.Uroguanylin,an intestinal natriuretic peptide,is elivered to the kidney as an unprocessedpropeptide[J].Endocrinology,2008,149:4486-4498.
4
Qian X, MossNG, Fellner RC,et al.Circulating prouroguanylin is processed toits active natriuretic form exclusively within the renal tubules[J].Endocrinology,2008,149:4499-4509.
5
Wasinger VC, Yau Y, Duo X,et al.Low mass blood peptides discriminative of inflammatory bowel disease(IBD)severity:a quantitative proteomic perspective[J].Mol Cell Proteomics,2016,15:256-265.
6
中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J].中华炎性肠病杂志,2018,2(3):173-190.
7
Dye FS, Larraufie P, Kay R,et al.Characterisation of proguanylin expressing cells in the intestine-evidence for constitutive luminal secretion[J].Sci Rep,2019,9:15574.
8
Brenna O, Bruland T, Furnes MW,et al.The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease[J].Scand J Gastroenterol,2015,50:1241-1252.
9
Han XN, Mann E, Gilbert S,et al.Loss of guanylyl cyclase C(GCC)signaling leads to dysfunctional intestinal barrier[J].Plos One,2011,6:e16139.
10
Wu F, Zhang SM, Dassopoulos T,et al.Identification of MicroRNAs Associated with Ileal and Colonic Crohn′s Disease[J].Inflammatory Bowel Dis,2010,16:1729-1738.
11
Brenna O, Furnes MW, Munkvold B,et al.Cellular localization of guanylin and uroguanylin mRNAs in human and rat duodenal and colonic mucosa[J].Cell Tissue Res,2016,365:331-341.
12
Brierley SM.Guanylate cyclase-C receptor activation:unexpected biology[J].Curr Opin Pharmacol,2012,12:632-640.
13
Priyamvada S, Gomes R, Gill RK,et al.Mechanisms underlying dysregulation of electrolyte absorption in inflammatory bowel disease-associated diarrhea[J].Inflamm Bowel Dis,2015,21:2926-2935.
14
Lan D, Niu J, Miao J,et al.Expression of guanylate cyclase-C,guanylin,and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index[J].Sci Rep,2016,6:25034.
15
Fellner RC, Moss NG, Goy MF.Dietary salt regulates uroguany-lin expression and signaling activity in the kidney,but not in the intestine[J].Physiol Rep,2016,4:e12782.
16
Qian X, Moss NG, Fellner RC,et al.The rat kidney contains high levels of prouro-guanylin(the uroguanylin precursor)but does not express GC-C(the enteric uroguanylin receptor)[J].Am J Physiol Renal Physiol,2011,300:F561-573.
17
Valentino MA, Lin JE, Snook AE,et al.Auroguanylin-GUCY2C endocrine axis regulates feeding in mice[J].J Clin Invest,2011,121:3578-3588.
[1] 郑凯, 黄敏, 庞智, 褚行琦, 邓学东. 小肠克罗恩病的经腹超声图像特征分析[J]. 中华医学超声杂志(电子版), 2020, 17(10): 970-976.
[2] 兰平. 克罗恩病手术的功能保护与取舍[J]. 中华普通外科学文献(电子版), 2021, 15(06): 436-436.
[3] 覃海波, 范洲, 陈文豪, 丁召, 钱群. 疑诊克罗恩病的鉴别探讨:附4例分析[J]. 中华普通外科学文献(电子版), 2021, 15(01): 52-54.
[4] 陈丽莉, 高天明, 王文晶, 冯旰珠. 克罗恩病合并肺结节一例报告并文献复习[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 597-599.
[5] 秦富豪, 郑正, 江滨. 间充质干细胞在克罗恩病肛瘘治疗中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 172-177.
[6] 陈文豪, 张亦超, 覃海波, 范洲, 胡航, 钱群, 江从庆, 丁召. 顺蠕动侧-侧吻合在克罗恩病结肠部分切除中的应用[J]. 中华结直肠疾病电子杂志, 2021, 10(05): 541-546.
[7] 王秀, 王义国. 乌司奴单抗治疗克罗恩病肛周瘘管的有效性和安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 514-519.
[8] 朱风尚, 舍玲, 丁永年, 杨长青. 警惕炎症性肠病与少见肠道疾病的鉴别诊断[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 273-276.
[9] 于晓东, 李德华, 高山, 徐鑫. 理中汤加味联合美沙拉嗪治疗轻度活动期克罗恩病的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 199-202.
[10] 陈婷婷, 江学良, 余佳丽, 柯剑林. 干细胞治疗炎症性肠病的安全性[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 193-198.
[11] 余佳丽, 江学良. 从炎症性肠病治疗策略转变看生物制剂应用进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(03): 129-134.
[12] 王梦, 徐东燕, 张晓雨, 赵海剑. 伴有肛周疾病的炎症性肠病患者肛门功能及生活质量分析[J]. 中华消化病与影像杂志(电子版), 2022, 12(04): 224-227.
[13] 杨翠萍, 全旭, 孙顺昌, 张梦茵, 张金叶, 贾颖, 俞骁珺, 谢玲, 蔡波尔, 吴云林, 陈平. 上海市嘉定区炎症性肠病患者的粪便钙卫蛋白检测研究[J]. 中华消化病与影像杂志(电子版), 2021, 11(05): 193-195.
[14] 葛文松. 提高克罗恩病早诊早治水平改善疗效和预后[J]. 中华消化病与影像杂志(电子版), 2021, 11(01): 28-30.
[15] 马昕, 金萌, 宁慧娟, 刘文雯, 宫幼喆, 张艳玲, 钟雪梅. 小肠胶囊内镜在儿童克罗恩病患者中的应用[J]. 中华胃肠内镜电子杂志, 2023, 10(03): 185-189.
阅读次数
全文


摘要